GSK (GSK) Set to Announce Earnings on Wednesday

GSK (NYSE:GSK) will be releasing its earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.95 per share for the quarter. GSK has set its FY 2024 guidance at 1.640-1.690 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). The business had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Price Performance

GSK stock opened at $41.63 on Tuesday. The business has a 50 day moving average price of $41.82 and a 200 day moving average price of $39.01. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The stock has a market cap of $86.28 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 1.44 and a beta of 0.64. GSK has a fifty-two week low of $33.33 and a fifty-two week high of $43.84.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a dividend of $0.3564 per share. This represents a $1.43 annualized dividend and a dividend yield of 3.42%. The ex-dividend date was Thursday, February 22nd. This is an increase from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is currently 52.82%.

Analysts Set New Price Targets

A number of research analysts recently commented on GSK shares. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley initiated coverage on GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.